CIDR Standardizes on Illumina Technology
News Feb 16, 2006
Illumina, Inc. has announced that the Center for Inherited Disease Research (CIDR) will offer investigators a genome-wide association (GWA) service based on Illumina's Sentrix® HumanHap300 BeadChip and Infinium™ assay.
The decision follows performance testing of the BeadChips and Infinium assay reagents as part of a Type 2 diabetes pilot study.
According to David Valle, M.D., Director, CIDR and Professor, Institute of Genetic Medicine, Johns Hopkins University, "Our evaluation of Illumina's WGA solution yielded impressive results and very high data quality."
"We observed call rates exceeding 99.6%, accuracy measures approaching 100%, and 99.85% concordance with HapMap genotypes. We look forward to collaborating with investigators on large-scale disease association studies."
CIDR's adoption of Illumina technology for genome-wide association studies complements the Center's SNP linkage and custom genotyping services that use the Illumina Array Matrix and GoldenGate® assay.
All SNP genotyping is performed within the Illumina BeadLab system, which features production-scale sample processing and uses LIMS to integrate workflows and ensure positive sample tracking.
Commenting on CIDR's adoption of Illumina solutions for whole-genome genotyping, Jay Flatley, Illumina CEO and President, stated, "We've been working closely with David Valle, Kim Doheny, Ph.D., Director of Genotyping at CIDR and their CIDR team for nearly three years, and we're thrilled to extend our relationship into the large-scale disease association area."
"We're also very pleased with the ease with which CIDR researchers were able to integrate Infinium genotyping into the existing BeadLab infrastructure."
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019